ISPC vs. APDN, RVYL, PAVS, GRNQ, HLGN, WWAC, QH, CAUD, LDWY, and ATIF
Should you be buying iSpecimen stock or one of its competitors? The main competitors of iSpecimen include Applied DNA Sciences (APDN), Ryvyl (RVYL), Paranovus Entertainment Technology (PAVS), Greenpro Capital (GRNQ), Heliogen (HLGN), Worldwide Webb Acquisition (WWAC), Quhuo (QH), Collective Audience (CAUD), Lendway (LDWY), and ATIF (ATIF). These companies are all part of the "business services" industry.
iSpecimen vs.
iSpecimen (NASDAQ:ISPC) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability.
iSpecimen has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Applied DNA Sciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
In the previous week, Applied DNA Sciences had 1 more articles in the media than iSpecimen. MarketBeat recorded 2 mentions for Applied DNA Sciences and 1 mentions for iSpecimen. Applied DNA Sciences' average media sentiment score of 0.50 beat iSpecimen's score of 0.38 indicating that Applied DNA Sciences is being referred to more favorably in the news media.
Applied DNA Sciences received 290 more outperform votes than iSpecimen when rated by MarketBeat users. However, 75.00% of users gave iSpecimen an outperform vote while only 58.02% of users gave Applied DNA Sciences an outperform vote.
13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 22.2% of Applied DNA Sciences shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by company insiders. Comparatively, 0.2% of Applied DNA Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Applied DNA Sciences has a consensus target price of $1.50, suggesting a potential upside of 728.73%. Given Applied DNA Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Applied DNA Sciences is more favorable than iSpecimen.
iSpecimen has a net margin of -91.66% compared to Applied DNA Sciences' net margin of -203.76%. Applied DNA Sciences' return on equity of -111.18% beat iSpecimen's return on equity.
Applied DNA Sciences has lower revenue, but higher earnings than iSpecimen. iSpecimen is trading at a lower price-to-earnings ratio than Applied DNA Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Applied DNA Sciences beats iSpecimen on 13 of the 18 factors compared between the two stocks.
Get iSpecimen News Delivered to You Automatically
Sign up to receive the latest news and ratings for ISPC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iSpecimen Competitors List
Related Companies and Tools
This page (NASDAQ:ISPC) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ISPC Stock Alerts